Your browser doesn't support javascript.
loading
Safety and immunogenicity of COVID-19 vaccination in patients with hepatocellular carcinoma (CHESS-NMCID 2101): A multicenter prospective study.
Qi, Xiaolong; Wang, Jitao; Zhang, Qiran; Ai, Jingwen; Liu, Chuan; Li, Qianqian; Gu, Ye; Lv, Jiaojian; Huang, Yifei; Liu, Yanna; Xu, Dan; Chen, Shubo; Liu, Dengxiang; Li, Jinlong; Xiang, Huiling; Liang, Jing; Bian, Li; Zhang, Zhen; Liu, Luxiang; Zhang, Xuying; Qin, Wei; Wang, Xiaodong; Hou, Zhiyun; Zhang, Nina; Zhang, Aiguo; Zu, Hongmei; Wang, Yun; Yan, Zhaolan; Du, Xiufang; Hou, Aifang; Ji, Jiansong; Yang, Jie; Huang, Jiansheng; Zhao, Zhongwei; Zou, Shengqiang; Ji, Hailei; Ge, Guohong; Zeng, Qing-Lei; Zhang, Wenhong.
Afiliação
  • Qi X; Department of Radiology, Medical School, Center of Portal Hypertension, Zhongda Hospital, Southeast University, Nanjing, China.
  • Wang J; Department of Radiology, Medical School, Center of Portal Hypertension, Zhongda Hospital, Southeast University, Nanjing, China.
  • Zhang Q; CHESS-COVID-19 Group, Xingtai People's Hospital, Xingtai, Hebei, China.
  • Ai J; Department of Infectious Diseases, Huashan Hospital Affiliated to Fudan University, Shanghai, China.
  • Liu C; Department of Infectious Diseases, Huashan Hospital Affiliated to Fudan University, Shanghai, China.
  • Li Q; Department of Radiology, Medical School, Center of Portal Hypertension, Zhongda Hospital, Southeast University, Nanjing, China.
  • Gu Y; Department of Hepatology and Gastroenterology, The Third Central Hospital of Tianjin, Tianjin, China.
  • Lv J; CHESS-COVID-19 Group, The Sixth People's Hospital of Shenyang, Shenyang, Liaoning, China.
  • Huang Y; Department of Infectious Diseases, Lishui People's Hospital, Lishui, Zhejiang, China.
  • Liu Y; Department of Radiology, Medical School, Center of Portal Hypertension, Zhongda Hospital, Southeast University, Nanjing, China.
  • Xu D; Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
  • Chen S; Department of Radiology, Medical School, Center of Portal Hypertension, Zhongda Hospital, Southeast University, Nanjing, China.
  • Liu D; CHESS-COVID-19 Group, Xingtai People's Hospital, Xingtai, Hebei, China.
  • Li J; CHESS-COVID-19 Group, Xingtai People's Hospital, Xingtai, Hebei, China.
  • Xiang H; CHESS-COVID-19 Group, Xingtai People's Hospital, Xingtai, Hebei, China.
  • Liang J; Department of Hepatology and Gastroenterology, The Third Central Hospital of Tianjin, Tianjin, China.
  • Bian L; Department of Hepatology and Gastroenterology, The Third Central Hospital of Tianjin, Tianjin, China.
  • Zhang Z; CHESS-COVID-19 Group, The Sixth People's Hospital of Shenyang, Shenyang, Liaoning, China.
  • Liu L; CHESS-COVID-19 Group, The Sixth People's Hospital of Shenyang, Shenyang, Liaoning, China.
  • Zhang X; Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
  • Qin W; Clinal Laboratory, Lishui People's Hospital, Lishui, Zhejiang, China.
  • Wang X; Department of Gastroenterology, Baoding people's Hospital, Baoding, Heibei, China.
  • Hou Z; Department of Gastroenterology, Baoding people's Hospital, Baoding, Heibei, China.
  • Zhang N; Department of Hepatobiliary Surgery, Jincheng People's Hospital, Jincheng, Shanxi, China.
  • Zhang A; Department of Hepatobiliary Surgery, Jincheng People's Hospital, Jincheng, Shanxi, China.
  • Zu H; Department of Hepatobiliary Surgery, Jincheng People's Hospital, Jincheng, Shanxi, China.
  • Wang Y; Department of Gastroenterology, The Fourth People's Hospital of Qinghai Province, Xining, Qinghai, China.
  • Yan Z; Department of Gastroenterology, The Fourth People's Hospital of Qinghai Province, Xining, Qinghai, China.
  • Du X; Department of Gastroenterology, The Fourth People's Hospital of Qinghai Province, Xining, Qinghai, China.
  • Hou A; Department of Liver Diseases, The Third People's Hospital of Linfen City, Linfen, Shanxi, China.
  • Ji J; Department of Liver Diseases, The Third People's Hospital of Linfen City, Linfen, Shanxi, China.
  • Yang J; CHESS-COVID-19 Group, Lishui Hospital of Zhejiang University, Lishui, Zhejiang, China.
  • Huang J; CHESS-COVID-19 Group, Lishui Hospital of Zhejiang University, Lishui, Zhejiang, China.
  • Zhao Z; CHESS-COVID-19 Group, Lishui Hospital of Zhejiang University, Lishui, Zhejiang, China.
  • Zou S; CHESS-COVID-19 Group, Lishui Hospital of Zhejiang University, Lishui, Zhejiang, China.
  • Ji H; Department of Hepatology, Zhenjiang Third Hospital Affiliated to Jiangsu University, Zhenjiang, Jiangsu, China.
  • Ge G; Department of Hepatology, Zhenjiang Third Hospital Affiliated to Jiangsu University, Zhenjiang, Jiangsu, China.
  • Zeng QL; Department of Hepatology, Zhenjiang Third Hospital Affiliated to Jiangsu University, Zhenjiang, Jiangsu, China.
  • Zhang W; Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
J Med Virol ; 94(11): 5553-5559, 2022 11.
Article em En | MEDLINE | ID: mdl-35811309
Data on safety and immunogenicity of coronavirus disease 2019 (COVID-19) vaccinations in hepatocellular carcinoma (HCC) patients are limited. In this multicenter prospective study, HCC patients received two doses of inactivated whole-virion COVID-19 vaccines. The safety and neutralizing antibody were monitored. Totally, 74 patients were enrolled from 10 centers in China, and 37 (50.0%), 25 (33.8%), and 12 (16.2%) received the CoronaVac, BBIBP-CorV, and WIBP-CorV, respectively. The vaccines were well tolerated, where pain at the injection site (6.8% [5/74]) and anorexia (2.7% [2/74]) were the most frequent local and systemic adverse events. The median level of neutralizing antibody was 13.5 (interquartile range [IQR]: 6.9-23.2) AU/ml at 45 (IQR: 19-72) days after the second dose of vaccinations, and 60.8% (45/74) of patients had positive neutralizing antibody. Additionally, lower γ-glutamyl transpeptidase level was related to positive neutralizing antibody (odds ratio = 1.022 [1.003-1.049], p = 0.049). In conclusion, this study found that inactivated COVID-19 vaccinations are safe and the immunogenicity is acceptable or hyporesponsive in patients with HCC. Given that the potential benefits may outweigh the risks and the continuing emergences of novel severe acute respiratory syndrome coronavirus 2 variants, we suggest HCC patients to be vaccinated against COVID-19. Future validation studies are warranted.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Vacinas contra COVID-19 / COVID-19 / Neoplasias Hepáticas Tipo de estudo: Clinical_trials / Observational_studies Limite: Humans Idioma: En Revista: J Med Virol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Vacinas contra COVID-19 / COVID-19 / Neoplasias Hepáticas Tipo de estudo: Clinical_trials / Observational_studies Limite: Humans Idioma: En Revista: J Med Virol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China